The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
I’m happy with Chris Blackwell leading the company and to get the Japanese deal completed. He’s a man with a plan.
Nfx with find a new ceo all in good time but for now I would prefer Chris B to sort this deal out and update when the market with the best deal for the company and it’s shareholders. Gla
Rerate coming July through to August - NXP004 update, CEO update, Financial year end with possible Ebers and VistaGen update..... plus NXP002 Japanese deal.
Not even going to try and predict a SP on all above if good!! gla
Bed an isa from experience has usually always been at the bottom of the spread with a tiny variance in transfer trade around £150.
This is at the buy side and also pushed the SP up. Looks like negotiate trades to me.
Initial data received is very promising and suggests NXP004 has a significantly superior anti-fibrotic action compared to currently approved therapies. The pilot study is expected to complete in the coming weeks and the Company will update shareholders once the resulting data has been considered.
27th May so few weeks already past. Suspect news soon on this.
As Dan mentioned in the RNS
NXP004 - Initial data received is very promising and suggests NXP004 has a significantly superior anti-fibrotic action compared to currently approved therapies.
VistaGen
Ebers
NXP002 - The Company has previously announced that negotiations for out-licensing commercial rights in Asia are underway. These are in advanced negotiations
Money in the bank from placing!
I’m pretty happy with all this and happy to sit back and wait
Can we stick to NFX discussions! I’ve been invested here a long time! I have a large holding and will continue to add all the way back up to the teens.
I’m invested in NFX because I believe it will be huge one day. Gla